Non-invasive structural tissue analysis for low-cost, highly accurate, safe and rapid cancer diagnosis.
Non-invasive structural tissue analysis for low-cost, highly accurate, safe and rapid cancer diagnosis.
批准号:
10063925
负责人:
金额:
$49.11万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
~50% of the global population will develop cancer in their lifetime \[WHO,2022\]. Breast cancer is the most common form, with 685,000 deaths/year globally \[WHO,2021\]. The economic cost of cancer is significant with the last estimate of the global economic cost at ~1.5% of Global GDP(£735bn). In the UK, the economic cost of cancer was estimated at £7.6bn/year in 2020 and is expected to rise with the ageing population \[PharmaTimes,2020\]. Early diagnosis of cancer is key to improving chances of survival. Furthermore, monitoring the efficacy of treatment is vital to health outcomes, as well as identifying/demonstrating/measuring treatment efficacy.As the global population rises, the number of cancer cases is expected to increase, driving the need for improved diagnostics. Current-state-of-the-art cancer diagnostics are limited to either invasive techniques that have limited specificity and selectivity or non-invasive techniques that are highly expensive. Both invasive and non-invasive techniques require a hospital appointment, limiting the uptake of screening programs. Hence, there is a rapidly growing need for improved cancer diagnostics.EosDx in collaboration with Keele University is looking to develop and optimise 'NISTA', a non-invasive structural tissue analysis device offering safe and accurate cancer diagnosis and monitoring. The consortium possesses leading expertise in x-ray diffraction, structural crystallography and tissue analysis and has previously developed game-changing technologies within the diagnostic sector.In this project, the consortium will focus on optimising the NISTA diagnostic device, enabling cancer diagnosis through X-ray diffraction imaging. The NISTA diagnostic improves significantly over current-state-of-the-art as it enables pre-symptomatic, rapid, safe, non-invasive and highly accurate cancer diagnostics.This highly innovative project aims to expand the diagnostics sector from within the UK, driving the growth of a completely new industry sub-segment
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于深穿透拉曼光谱的安全光照剂量的深层病灶无创检测与深度预测
-
批准号:82372016
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:林俐
-
依托单位: